Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...

More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly ...

Ian C. Cook, MD, discusses the feasibility and benefits of adding bilateral salpingectomy to nongynecologic surgery.

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who ...

Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...

Novel drug combinations that improve outcomes, outstanding questions about treatment sequence, and encouraging results in chemotherapy resistant disease are among the ovarian cancer highlights ...

Ovarian cancer is one of the most common forms of cancer, a type that usually remains undiagnosed for a while in many ...

ORR for BI-1808 combined with pembrolizumab represents a meaningful improvement over pembrolizumab monotherapy in recurrent ...

Robust objective response rates were observed (31% overall, 44% in KRAS-mutant, and 17% in KRAS wild-type) in patients whose cancer had progressed after multiple prior lines of therapy The majority of ...

A sponge-like gold nanoparticle platform could deliver faster, more accurate, and less invasive ovarian cancer diagnostics.

In the future, scientists could use drugs made from cannabis to fight ovarian cancer. A team of scientists testing the ...